Andelyn Biosciences, a cell and gene therapy CDMO, has signed a license agreement with the Broad Institute to expand its AAV Curator platform.
The company will now include MyoAAV plasmids in the offering, which are 10x more efficient in reaching muscle tissue than wild-type vectors, according to the company.
They are also able to target muscle tissue precisely, potentially reducing the required dose of an associated therapeutic required for optimal efficacy.
The license allows Andelyn to use the Broad Institute’s MyoAAV plasmids for the company’s research and development purposes, allowing clients to determine if the plasmid type is compatible with their cell or gene therapy.
It also allows Andelyn to sublicense these plasmids to its clients for internal research.
Andelyn’s Chief Commercial Officer Matt Niloff, said: ”Our license from the Broad Institute furthers our goal of providing the industry access to critical tools and capabilities that facilitate the development of innovative therapies to bring more treatments to more patients. With access to the increased specificity of MyoAAVs, our clients now have the opportunity to maximize efficiency in their gene therapy processes and drive down the cost per patient.”
According to the company, its expertise in translational drug development will bring Broad’s novel AAV offerings to biotechnology organisations globally, allowing them to target therapeutic areas which currently have a significant unmet need.
